Toolbox 206: Helping to Prevent Fractures in Your Patients

In cardiovascular disease we strive to prevent recurrent events (like heart attack or stroke) by intervening right after the event. Fractures are "bone attacks". Let’s have the same intention and attention to our patient’s bones to prevent “bone attacks”.

This resource is intended to help achieve that goal. Take a tour to see what these expert physicians are doing in that regard. You will gain some clinical pearls and tools to help you to help your patients towards the goal of no more fractures.

Expert Steering Committee

	Planning Committee Member	Disclosures
	Jonathan D Adachi, MD, FRCPC The Actavis Chair in Rheumatology for Better Bone Health Professor, Department of Medicine Michael G. DeGroote School of Medicine St. Joseph’s Healthcare McMaster University Hamilton, ON	Dr. Adachi received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Acativs, AgNovos, Amgen, Eli Lilly, Merck, and Radius.
	Algis V. Jovaisas, MD FRCPC Rheumatology Adjunct Professor of Medicine Department of Medicine Faculty of Medicine University of Ottawa Ottawa ON	Dr. Jovaisas received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Alexion, Amgen, Celltrion, Eli Lilly, Gilead, Novartis, Pfizer, Sandoz, and Sanofi-Genzyme.
	Jodie M. Reis BHK, MD, FRCPC Rheumatology Associates of Saskatoon Physician lead – Saskatoon Fracture Liaison Service (FLS) Associate Program Director, CBD lead Rheumatology, University of Saskatchewan Assistant Professor, University of Saskatchewan Saskatoon, SK	Dr. Reis received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Amgen, Hospira, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, and UCB.

This non-accredited learning activity is financially supported by Amgen Canada and is for healthcare professionals only. This content was developed in concert with the scientific planning committee members and is based on current clinical practice guidelines or expert consensus.